NEW YORK, NY / ACCESSWIRE / August 30, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
3M Company (NYSE:MMM)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/3m-company-loss-submission-form?prid=3280&wire=1
Lead Plaintiff Deadline: September 27, 2019
Class Period: February 9, 2017 to May 28, 2019
Allegations against MMM include that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances (“PFAS”) are toxic (which was first publicly revealed in February 2018 by Minnesota’s Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.
Mallinckrodt Public Limited Company (NYSE:MNK)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mallinckrodt-public-limited-company-loss-submission-form?prid=3280&wire=1
Lead Plaintiff Deadline: September 24, 2019
Class Period: February 28, 2018 to July 16, 2019
Allegations against MNK include that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Evolent Health, Inc. (NYSE:EVH)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/evolent-health-inc-loss-submission-form?prid=3280&wire=1
Lead Plaintiff Deadline: October 7, 2019
Class Period: March 3, 2017 to May 28, 2019
Allegations against EVH include that: (1) Evolent's partnership model was not aligned with its partners, as it was designed to parasitically increase its own revenue by extracting enormous administrative and management fees at the expense of its partners such as Passport Health Plan ("Passport"); (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees, and money to such an extent that Passport was left on the verge of insolvency; (4) for several months, Passport was conducting a bidding process to sell itself to a financial buyer to prevent liquidation; and (5) as a result of the foregoing, Defendants public statements were materially false and/or misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong